Please login to the form below
Vidaza
This page shows the latest Vidaza news and features for those working in and with pharma, biotech and healthcare.
BMS’s oral AML therapy Onureg receives EU approval
Onureg is the oral version of Vidaza, two of the drugs BMS gained as part of its acquisition of Celgene in 2019. ... Onureg is the oral version of Vidaza, two of the drugs BMS gained as part of its acquisition of Celgene for $74bn in 2019.
Latest news
-
J&J exits $1.6bn blood cancer drug licensing deal with argenx
The ongoing, early-stage trial is evaluating cusatuzumab in combination with AbbVie/Roche’s Venclexta (venetoclax) and chemotherapy Vidaza (azacitidine) in newly-diagnosed, elderly patients with AML.
-
BMS’ oral maintenance therapy boosts survival in AML patients
CC-486 is an oral version of Celgene’s already-marketed chemotherapy Vidaza (azacitidine), which is administered intravenously – it had been a top-selling product for the company, before being hit ... Vidaza brought in over $600m a year at its peak,
-
Celgene’s ‘oral Vidaza’ clears phase 3 leukaemia trial
The formulation – known as CC-486 – is an orally-active version of Vidaza, Celgene’s already-marketed azacitidine product which is administered intravenously. ... Vidaza was a big seller for Celgene in the past but has been hit by generic
-
Dutch biotech Argenx claims $1.8bn licensing deal with J&J
It is being given in combination with Celgene’s Vidaza (azacitidine) and will look at escalating doses of Argenx’ drug, given intravenously, with a standard dose of Vidaza.
-
Celgene, Agios get FDA OK for leukaemia drug Idhifa
At Celgene, enasidenib will slot into its blood cancer therapy portfolio alongside Vidaza (azacitidine), a drug used first-line to treat AML patients who cannot receive a stem cell transplant, which ... A phase III trial of ivosidenib in combination with
More from news
Approximately 3 fully matching, plus 22 partially matching documents found.
Latest Intelligence
-
Chinese biotech’s global ambitions
Meanwhile, BeiGene entered into a strategic global collaboration with Celgene in 2017, gaining the rights to Celgene’s Abraxane Revlimid and Vidaza in China, while Celgene gained an option to market
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Country Manager, Healthcare Communications Agency, Germany
-
Highly competitive salary
- bluebird bio reveals plans to launch two gene therapies
- Sanofi halts recruitment for trials assessing MS treatment
- Eli Lilly to make bebtelovimab commercially available to US states from August
- The patient voice – the value of patient-reported outcomes in HTA
- AbbVie and Sosei Heptares collaborate in new agreement worth up to $1.2bn
- ONS records a continued fall in UK COVID-19 infections
- Powering Rapid Cognitive Analysis with AI
- How the Royal Society’s EiR programme can help to drive UK innovation
- BMS and 2seventy bio announce positive results for multiple myeloma treatment
- Roche and Cend Therapeutics to evaluate pancreatic cancer combination therapy
- Aqilion initiates phase 1 clinical trial for chronic inflammatory diseases
- JCVI publishes statement on London polio vaccination strategy
- Eli Lilly to make bebtelovimab commercially available to US states from August
- Amgen acquires ChemoCentryx in $3.7bn cash deal
- AstraZeneca’s Alexion agrees on $775m settlement with Chugai for Ultomiris
- EMA backs adjuvant use of Roche’s breast cancer ADC Kadcyla
- FDA approves Coherus’ Cimerli as biosimilar interchangeable with Lucentis for all five indications
- Gilead Sciences set to acquire MiroBio in deal worth over $400m
PMHub
Healthcare Media Europe – HME Ltd
HME are an innovative and technology enabled agency offering our clients over 35+ years of knowledge and expertise in delivering...
